I

InterCure Ltd
TASE:INCR

Watchlist Manager
InterCure Ltd
TASE:INCR
Watchlist
Price: 469.7 ILS 6.77%
Market Cap: 225.9m ILS

Relative Value

The Relative Value of one INCR stock under the Base Case scenario is 688.48 ILS. Compared to the current market price of 469.7 ILS, InterCure Ltd is Undervalued by 32%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

INCR Relative Value
Base Case
688.48 ILS
Undervaluation 32%
Relative Value
Price
I
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0.8
Median 5Y
1.2
Industry
2.6
Forward
0.6
vs History
vs Industry
Median 3Y
-3.8
Median 5Y
10
Industry
21.6
Forward
7
vs History
vs Industry
Median 3Y
-5.3
Median 5Y
-4.4
Industry
16.5
vs History
vs Industry
Median 3Y
-1.9
Median 5Y
-1.7
Industry
22.5
vs History
vs Industry
Median 3Y
0.6
Median 5Y
0.9
Industry
2.3
vs History
vs Industry
Median 3Y
0.8
Median 5Y
1.1
Industry
2.9
Forward
0.6
vs History
vs Industry
Median 3Y
2.5
Median 5Y
3.5
Industry
5.5
vs History
vs Industry
Median 3Y
5.9
Median 5Y
6.6
Industry
13
Forward
4.7
vs History
vs Industry
Median 3Y
7.8
Median 5Y
8.9
Industry
16.6
Forward
4.3
vs History
vs Industry
Median 3Y
-5.3
Median 5Y
-4.4
Industry
15.8
vs History
vs Industry
Median 3Y
-5.7
Median 5Y
-4.9
Industry
19.1
vs History
vs Industry
Median 3Y
0.5
Median 5Y
0.7
Industry
1.9

Multiples Across Competitors

INCR Competitors Multiples
InterCure Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IL
InterCure Ltd
TASE:INCR
225.9m ILS 0.6 -3.6 5.1 7.2
US
Eli Lilly and Co
NYSE:LLY
985.4B USD 16.6 53.5 35.9 38.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
506.1B USD 5.5 20.1 16.5 21.4
CH
Roche Holding AG
SIX:ROG
252.7B CHF 4.1 26.8 11.5 13.4
UK
AstraZeneca PLC
LSE:AZN
209.2B GBP 4.8 29.8 107.9 157.9
CH
Novartis AG
SIX:NOVN
206.9B CHF 4.6 18.1 11.5 14.8
US
Merck & Co Inc
NYSE:MRK
246.7B USD 3.8 13 9.2 11
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.3 13 9.1 10.6
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
142.4B USD 2.3 14.5 7.4 10.1
P/E Multiple
Earnings Growth PEG
IL
I
InterCure Ltd
TASE:INCR
Average P/E: 23.6
Negative Multiple: -3.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.5
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.1
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.8
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.8
38%
0.8
CH
Novartis AG
SIX:NOVN
18.1
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13
4%
3.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.5
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IL
I
InterCure Ltd
TASE:INCR
Average EV/EBITDA: 399.2
5.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.5
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.5
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
107.9
10%
10.8
CH
Novartis AG
SIX:NOVN
11.5
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.2
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.1
2%
4.6
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
1%
7.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IL
I
InterCure Ltd
TASE:INCR
Average EV/EBIT: 1 710.7
7.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.5
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.4
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.4
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
157.9
23%
6.9
CH
Novartis AG
SIX:NOVN
14.8
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.6
1%
10.6
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
8%
1.3